{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-058199","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2025-06-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.258493+00:00","generated_at":"2026-05-19T15:26:33.403259+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Iovance stockholders elect all director nominees, approve equity plan and audit ratification at annual meeting","bullets":["Annual meeting held June 10, 2025; 254,281,338 shares (76.1% of outstanding) represented.","All seven director nominees elected; vote tallies ranged from 97.8M (Countouriotis) to 166.9M (Rothbaum).","Non-binding advisory vote on executive compensation approved: 158.8M for, 14.5M against, 0.8M abstain.","Ratification of Ernst & Young as independent auditor approved: 248.4M for, 4.9M against.","Amendments to 2018 Equity Plan (+12.5M shares) and 2020 ESPP (+1M shares) approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-058199","json":"https://secwatch.observer/filing/0001104659-25-058199.json","markdown":"https://secwatch.observer/filing/0001104659-25-058199.md","text":"https://secwatch.observer/filing/0001104659-25-058199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/0001104659-25-058199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465925058199/tm2517622d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T15:26:33.403259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}